Number, type and cost of microbiological tests during HIV Pre-Exposure Prophylaxis: The experience of a French hospital

被引:1
作者
Morgat, M. [1 ]
Bouiller, K. [2 ]
Vuillemenot, J. B. [3 ]
Puget, L. [1 ]
Marty-Quinternet, S. [1 ]
Leblanc, T. [1 ]
Jeannot, K. [3 ]
Chirouze, C. [2 ]
Hustache-Mathieu, L. [2 ]
Lepiller, Q. [1 ,4 ]
机构
[1] CHU Besancon, Virol Lab, 3 Blvd Fleming, F-25030 Besancon, France
[2] CHU Besancon, Infect Dis Dept, Besancon, France
[3] CHU Besancon, Bacteriol Lab, Besancon, France
[4] Univ Bourgogne Franche Comte, EA3181, Besancon, France
来源
INFECTIOUS DISEASES NOW | 2021年 / 51卷 / 04期
关键词
PrEP; HIV; Microbiological assays; Sexually transmitted diseases; PREVENTION; MEN; SEX;
D O I
10.1016/j.medmal.2020.10.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Microbiological tests are required for individuals on HIV Pre-Exposure Prophylaxis (PrEP), but their real-life numbers, types and cost are poorly described. Methods: Number, type, and results of microbiological tests performed in a Besancon Hospital-associated laboratory, France, from 2016 to 2019, in the setting of PrEP consultations were retrospectively collected. Costs were estimated by the current reimbursement rate set by the French national protection system. Results: 756 consultations for PrEP initiation or follow-up of 135 persons were performed over 4 years. Among 3434 tests performed in the institution-associated laboratory, 1083 and 2351 were virological and bacteriological tests, respectively. Serology was predominant in virology (98% of virological tests), with HIV, HCV, and HBV screening as the 3 more frequent assays, whereas molecular biology was predominant in bacteriology (63.1% of bacteriological tests) with N. gonorrhoeae and C. trachomatis screening as leader assays. Agar-based culture accounted for 1% of bacterial tests. The global cost of microbiological tests was 45,983.20 euros, corresponding to a mean cost of 60.80 euros per consultation. Virological and bacteriological tests accounted for 37.7% and 62.3% of this budget, respectively. No seroconversion was observed for HIV or HCV. N. gonorrhoeae and C. trachomatis were detected at least once in 39.3% and 22.4% of individuals, respectively, with 15% of symptomatic episodes in both cases. Active syphilis infection was detected in 15.4% of individuals. Conclusions: Since numerous microbiological tests are required during PrEP, the availability of specific technical platforms should not be neglected by centers wishing to set up PrEP consultations. (C) 2020 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:357 / 361
页数:5
相关论文
共 19 条
[1]  
[Anonymous], Codage des actes biologiques-NABM
[2]  
Cambiano V, 2018, LANCET INFECT DIS, V18, P85, DOI [10.1016/S1473-3099(17)30540-6, 10.1016/s1473-3099(17)30540-6]
[3]   Assessment of HIV Screening Tests for Use in Preexposure Prophylaxis Programs [J].
Delaugerre, Constance ;
Antoni, Guillemette ;
Mahjoub, Nadia ;
Pialoux, Gilles ;
Cua, Eric ;
Pasquet, Armelle ;
Hall, Nolwenn ;
Tremblay, Cecile ;
Cotte, Laurent ;
Capitant, Catherine ;
Chaix, Marie-Laure ;
Meyer, Laurence ;
Molina, Jean-Michel .
JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (03) :382-386
[4]  
DGOS, 2020, REF ACT INN NOM BIOL
[5]  
Durand-Zaleski I, 2018, AIDS, V32, P95, DOI [10.1097/qad.0000000000001658, 10.1097/QAD.0000000000001658]
[6]   Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. [J].
Grant, Robert M. ;
Lama, Javier R. ;
Anderson, Peter L. ;
McMahan, Vanessa ;
Liu, Albert Y. ;
Vargas, Lorena ;
Goicochea, Pedro ;
Casapia, Martin ;
Guanira-Carranza, Juan Vicente ;
Ramirez-Cardich, Maria E. ;
Montoya-Herrera, Orlando ;
Fernandez, Telmo ;
Veloso, Valdilea G. ;
Buchbinder, Susan P. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Mayer, Kenneth H. ;
Kallas, Esper Georges ;
Amico, K. Rivet ;
Mulligan, Kathleen ;
Bushman, Lane R. ;
Hance, Robert J. ;
Ganoza, Carmela ;
Defechereux, Patricia ;
Postle, Brian ;
Wang, Furong ;
McConnell, J. Jeff ;
Zheng, Jia-Hua ;
Lee, Jeanny ;
Rooney, James F. ;
Jaffe, Howard S. ;
Martinez, Ana I. ;
Burns, David N. ;
Glidden, David V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (27) :2587-2599
[7]   Estimating the 'PrEP Gap': how implementation and access to PrEP differ between countries in Europe and Central Asia in 2019 [J].
Hayes, Rosalie ;
Schmidt, Axel J. ;
Pharris, Anastasia ;
Azad, Yusef ;
Brown, Alison E. ;
Weatherburn, Peter ;
Hickson, Ford ;
Delpech, Valerie ;
Noori, Teymur .
EUROSURVEILLANCE, 2019, 24 (41) :2-8
[8]   Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study [J].
Jenness, Samuel M. ;
Weiss, Kevin M. ;
Goodreau, Steven M. ;
Gift, Thomas ;
Chesson, Harrell ;
Hoover, Karen W. ;
Smith, Dawn K. ;
Liu, Albert Y. ;
Sullivan, Patrick S. ;
Rosenberg, Eli S. .
CLINICAL INFECTIOUS DISEASES, 2017, 65 (05) :712-718
[9]  
Juusola JL, 2012, ANN INTERN MED, V156, P541, DOI [10.7326/0003-4819-156-8-201204170-00004, 10.7326/0003-4819-156-8-201204170-00001]
[10]   Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial [J].
McCormack, Sheena ;
Dunn, David T. ;
Desai, Monica ;
Dolling, David I. ;
Gafos, Mitzy ;
Gilson, Richard ;
Sullivan, Ann K. ;
Clarke, Amanda ;
Reeves, Iain ;
Schembri, Gabriel ;
Mackie, Nicola ;
Bowman, Christine ;
Lacey, Charles J. ;
Apea, Vanessa ;
Brady, Michael ;
Fox, Julie ;
Taylor, Stephen ;
Antonucci, Simone ;
Khoo, Saye H. ;
Rooney, James ;
Nardone, Anthony ;
Fisher, Martin ;
McOwan, Alan ;
Phillips, Andrew N. ;
Johnson, Anne M. ;
Gazzard, Brian ;
Gill, Owen N. .
LANCET, 2016, 387 (10013) :53-60